Background
Colorectal cancer (CRC), one of the most common forms of malignancies in adults, ranks the third among leading causes of cancer-related death worldwide [
1]. Due to the high rate of metastasis and recurrence, the mortality rate of CRC patients remains high [
2]. Exploring the mechanisms underlying CRC progression will accelerate the search for the novel diagnostic biomarkers and the development of effective therapeutic target.
Analogous to histones and DNA, mRNAs can also be chemically modified [
3]. More than 100 structurally distinct chemical modifications have been detected in RNAs [
4,
5], among these, N6-methyladnosine(m6A) modification represents the most prevailing chemical mark in eukaryotic mRNAs [
6,
7]. M6A modification is mainly mediated by the m6A methyltransferases (writers), including methyltransferase-like 14 (METTL14) [
8], methyltransferase-like 3(METTL3) [
9], vir-Like m6A methyltransferase associated (KIAA1429) [
10] and Wilms tumor 1 associated protein (WTAP) [
11], and can be removed by m6A demethylases (erasers) consists of alkylation repair homolog protein 5 (ALKBH5) [
12] and fat-mass and obesity-associated protein (FTO) [
13]. m6A modification exerts its effects on mRNAs via recruiting reader proteins, mainly including YTH domain-containing family protein 1/2/3(YTHDF1/2/3), insulin-like growth factor 2 mRNA-binding proteins 1/2/3(IGF2BP1/2/3) and heterogeneous nuclear ribonucleoprotein family (HNRNPA2B1, HNRNPC) [
14,
15]. They are mainly involved in diverse biological regulatory processes, including RNA stability, translational regulation and primiRNA processing [
16,
17].
Increasing studies have shown that m6A modification and its associated regulatory proteins play provital roles in the pathogenesis of varieties types of malignancies, including gastric cancer (GC) [
18], hepatocellular cancer (HCC) [
19], bladder cancer [
20], breast cancer [
21], lung cancer [
22] and so on. However, the biological functions of m6A modification and knowledge of the mechanistic link among the m6A “writers”, “readers”, and “targets” remain largely elusive in CRC.
Our study unveiled that KDM5C-mediated demethylation of H3K4me3 lead to the inhibition of METTL14 in CRC. Moreover, we demonstrated the inhibitory role of METTL14 in CRC progression, and identified SOX4 as a downstream target of METTL14. Furthermore, METTL14 epigentically elevated SOX4 expression through a m6A-YTHDF2-dependent mechanism. Lastly, we found that inhibition of METTL14 in CRC promoted SOX4-mediated EMT process and activated SOX4-mediated PI3K/Akt signaling pathway. Taken together, we provide several new insights into METTL14-mediated m6A modification, and also uncover the molecular mechanism underlying CRC metastasis through identifying the downstream target genes and signals.
Methods
Analysis of public databases
The raw gene expression data in CRC were downloaded from The Cancer Genome Atlas (TCGA) (http://cancergenome.nih.gov) and GEO database. The independent data sets from (GSE9348 [
23], GSE44076 [
24‐
28], GSE41657) were analyzed in this study.
Cell culture
Human normal colonial epithelial cell lines (NCM460) and colorectal cancer cell lines (HCT116, HCT8, SW620, SW480, HT29 and DLD-1) were all obtained from American Type Culture Collection (ATCC). NCM460, HCT116 and HCT8 cells were cultured in RPMI-1640 supplemented with 10% fetal bovine serum (FBS, Hyclone, USA), and SW620, SW480, HT29 and DLD-1 were maintained in Dulbecco’s modified Eagle’s medium (DMEM) with 10% FBS. All these cells were cultured at 37 °C with 5% CO2.
Patients specimens and clinical data collection
A total of 136 CRC and corresponding adjacent normal tissues (ANTs) were collected from Nanjing First Hospital, Nanjing Medical Hospital. Our study was approved by the Institutional Review Board of Nanjing First Hospital, and written informed consent were obtained from all patients prior to our study. The patients who have achieved system treatment were not permitted in this study. The clinical characteristics in 136 CRC patients was presented in Table
1.
Table 1Correlation between METTL14 expression and different clinical characteristics.
Gender | | | | 0.727 |
Male | 81 (59.6%) | 39 (57.4%) | 42 (61.8%) |
Female | 55 (40.4%) | 29 (42.6%) | 26 (38.2%) |
Age (years) | | | | 0.716 |
< 60 | 45 (33.1%) | 24 (35.3%) | 21 (30.9%) |
≥ 60 | 91 (66.9%) | 44 (64.7%) | 47 (69.1%) |
Tumor invasion depth | | | | 0.162 |
T1-T2 | 81 (59.6%) | 45 (66.2%) | 36 (52.9%) |
T3-T4 | 55 (40.4%) | 23((33.8%) | 32 (47.1%) |
Lymph node metastasis | | | | 0.018 |
N0 | 46 (33.8%) | 30 (44.1%) | 16 (23.5%) |
N1 + N2 | 90((66.2%) | 38 (55.9%) | 52 (76.5%) |
Distant metastasis | | | | 0.002 |
M0 | 117 (86.0%) | 65 (95.6%) | 52 (76.5%) |
M1 | 19 (14.0%) | 3((4.4%) | 16 (23.5%) |
TNM stage | | | | 0.005 |
I-II | 83 (61.0%) | 50 (73.5%) | 33 (48.5%) |
III-IV | 53 (39.0%) | 18 (26.5%) | 35 (51.5%) |
Transwell assays
For transwell migration and invasion assays, CRC cells were seeded into the upper chamber without (transwell migration assay) or with (transwell invasion assay) matrigel (BD Biosciences, USA). After 24 h of incubation, non-migrated or invaded CRC cells were scraped off using a cotton swab, and CRC cells on the bottom of chamber were fixed with methanol for 10 min, and stained using 0.5% crystal violet. Then 5 fields(× 200 magnification) were selected and photographed randomly using an inverted microscope (Nicon, Japan). The experiments were performed in triple.
Quantitative real-time PCR
TRIzol Reagent (Invitrogen, USA) was employed to extract total RNA from CRC tissues and cells following manufacturer’s instructions. The mRNA levels was assessed using PrimeScript RT reagent Kit and SYBR Premix Ex Taq (Takara, Dalian, China). All results were normalized to GAPDH. The relative expression of mRNAs was quantified using the 2
–∆∆Ct method. The primers used are listed in Additional file
1: Table S1.
Plasmid construction and cell transfection
The full-length complementary cDNAs of human METTL14 and SOX4 were synthesized and cloned into the pcDNA3.1(Invitrogen, China). The small hairpin RNA (shRNA) targeting KDM5C, METTL14, SOX4, YTHDF1, YTHDF2 and YTHDF3 were designed and synthesized by GenePharma (Shanghai, China). The shRNA of SOX4, METTL14 and their negative control were synthesized and cloned into the pGLVH1/GFP/Puro vector (GenePharma, China). The plasmids were transfected into CRC cells using lipofectamine 3000(Invitrogen, USA) in accordance with the protocol. The sequences of shRNAs were supplemented in Additional file
1: Table S1. To achieved the METTL14 and SOX4 stable knockdown cell line, HCT116 cells were infected with LV-shMETTL14–1, LV-shSOX4 and LV-NC, and selected using 10 μg/ml puromycin.
RNA stability
To measure RNA stability in METTL14 stable knockdown or control HCT116 cells, actinomycin D (MCE, USA) at 5 μg/ml was added to cells, and the cells were collected after incubation at the indicated times (0, 1, 2, 4, 8 h), and RNA was isolated from these cells for qRT-PCR.
Chromatin immunoprecipitation assay
The chromatin immunoprecipitation (ChIP) assay kit (Beyotime, China) was employed to fulfill the ChIP assay following the manufacturer’s instruction. In brief, CRC cells were collected and soniacated to generate DNA fragments ranging from 200 to 500 bp. Then the lysate was immunoprecipitated with anti-KDM5C, anti-H3K4me3 or IgG antibodies (negative control) overnight. Immunoprecipitated DNAs were extracted and analyzed by qPCR. The 2000 bp upstream and 500 bp downstream of the METTL14 promoter were divided into eight parts(C1, C2, C3, C4, C5, C6, C7, C8), and the ChIP primer sequences were listed in Additional file
1: Table S3.
Animal experiments
All animal experiments were approved by the animal care Committee of Nanjing First Hospital, Nanjing Medial University (acceptance No. SYXK 20160006). 2 × 106 transfected HCT116 cells in 0.2 ml PBS were injected into the tail vein of nude mice which were randomly divided into nine groups (eight mice per group). After 2 months of injection, mice were sacrificed, and their lungs were removed and stained by Hematoxylin and Eosin (HE) Staining.
Statistical analysis
All data analysis in our study were performed using GraphPad Prism 6(GraphPad, USA) and SPSS 18.0(SPSS, USA) software. Student’s t-test was employed to detect the differences in gene expression. A chi-square test was conducted to analyze the distribution differences of the variables, the Pearson correlation coefficient was employed to assess the correlation of expression. The survival curves were compared with log-rank test. Follow-up time was censored if the patient was lost to follow-up. Cox proportional hazards model was employed to perform univariate and multivariate analysis and calculate the 95% confidence interval (95% CI). P < 0.05 was considered statistically significant, data in our work are expressed as the mean ± standard deviation (SD) from more than three independent experiments.
A complete description of the methods, including Western blot, Immunohistochemistry (IHC) analysis, RNA m6A dot blot, RNA immunoprecipitation (RIP), RNA-Seq and MeRIP-Seq and Luciferase Reporter Assays are available in Additional file
2: supplementary materials and methods.
Discussion
Numerous layers of epigenetic modulation that arise from modification of DNA and proteins have been well studied, but RNA modification are still elusive [
3]. Similar to DNA modification, over 100 types of post-transcriptional modifications have been identified in all RNA species. Among these modifications, RNA m6A modification account for more than 80% of RNA modification, and have been reported to be play significant roles in pre-mRNA splicing, miRNA processing, translation regulation and mRNA decay [
35,
36]. METTL14, acting as the central component of N6-methytransferse complex, has been verified to be dysregulated and involved in the initiation and progression of various malignancies. In the present study, we unveiled that METTL14 was significantly downregulated in CRC tissues, and deceased METTL14 was accompanied by a poor CRC prognosis. Subsequently, to identify the reason for low METTL14 in CRC, we analyzed the ChIP-Seq results from ENCODE database, we focused on H3K4me3 and proved that KDM5C-mediated demethylation of H3K4me3 inhibited METTL14 transcription and lead to the suppression of METTL14 in CRC through ChIP and western blot assays. Then we found that METTL14 was significantly downregulated in CRC cell lines, especially in HCT116 and HCT8 cell lines, and we selected HCT116 and HCT8 cell lines with lower METTL14 for follow-up experiments. Suppression of METTL14 markedly promoted the ability of migration and invasion, whereas overexpression of METTL14 suppressed the ability of migration and invasion in HCT116 and HCT8 cells. Similarly, in vivo experiments indicated that METTL14 knockdown promoted HCT116 cells metastasis, while METTL14 upregulation inhibited HCT116 cells metastasis. These results confirmed that METTL4 function as a tumor suppressor in CRC.
To further address the role of METTL14, we combined the data from RNA-Seq and MeRIP-Seq to reveal that SOX4 might be the downstream target of METTL14, and the m6A enrichment region of SOX4 located around the stop codon. SOX4 was negatively regulated by METTL14 and modified by METTL14-intermediated m6A methylation as detected using MeRIP-qPCR and luciferase reporter assays.
M6A reader proteins (IGF2BP1/2/3, eIF3, YTHDF1/2/3 and so on) can bind to m6A modified motif indirectly or directly to affect RNA function [
37]. Here, we found that YTHDF2 knockdown could augment the SOX4 expression in CRC cells. Through RNA stability assay, Half-life of SOX4 mRNA in METTL14 stable knockdown HCT116 cells was found to be significantly longer than that in control cells, m6A modification could trigger mRNA degradation via the m6A reader protein YTHDF2 [
38], and we also detected that YTHDF2 could bind to SOX mRNA through YTHDF2-RIP assay. These data indicated that SOX4 was a target of YTHDF2 in CRC.
SOX4 is a prominent tumor-related transcription factor and its expression is increased in multitude of human cancers, and has been demonstrated to participant in the TGF-β induced EMT, a process closely associated with increases in migrative and invasive capacity, in metastasis and in chemotherapy drug resistance [
14,
39,
40]. Moreover, SOX4 was reported to be involved in many pathways that are commonly activated in various cancers, including PI3K/Akt signaling [
41], Wnt signaling [
42,
43] and MAPK signaling [
44]. In this study, we validated the mRNA and protein levels of SOX4 were significantly upregulated in CRC tissues. Depletion of SOX4 could markedly suppress the ability of migration and invasion, while the inhibitory effect caused by METTL14 overexpression could be reversed by SOX4 upregulation in CRC cells, and the results of in vivo experiments were in agreement with those in vitro experiments. Furthermore,to better understand the underlying molecular mechanism of METTL14 in CRC, on the one hand, we found that METTL14 knockdown could elevate the expression of Vimentin and N-cadherin, and decrease the expression of E-cadherin, in other words, METTL14 knockdown facilitates EMT process in CRC, and this promption could be reversed by the depletion of SOX4, on the other hand, we noticed that loss of METTL14 could activate PI3K/Akt signaling, and this activation was abrogated by disruption of SOX4 in CRC. LY294002, a chemical inhibitor of PI3K, could obviously inactivate PI3K/Akt signaling as well as impair the ability of the migration and invasion in HCT116 and HCT8 cells. Taken together, these results indicated inhibition of METTL14 in CRC promoted SOX4-mediated EMT process and activated SOX4-mediated PI3K/Akt signaling pathway.
In summary, our current work elucidated the key role of METTL14-mediated m6A modification in human CRC progression and a charmingm6A-dependent regulatory mechanism. We demonstrated that METTL14 epigenetically inhibited the expression of SOX4 via an m6A-YTHDF2-dependent mechanism. The discovery of the METTL14/SOX4 axis and its impact on CRC metastasis will aid in further CRC study and in exploring efficient therapeutic strategies against CRC.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.